Industrial and Intellectual Property
-
When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy [2018]
- Category:
- Artículos
- Authors:
- Ildiko Lingvay , Elías Delgado Álvarez , Angelo Avogaro
- Date:
- 01 of January of 2018
- It Is a Part of:
- Diabetes/Metabolism Research and Reviews, 34